Biogen Inc Live Discussion of Cerebrospinal Fluid Biomarker Concordance with Amyloid PET in EMERGE and ENGAGE at AD/PD Transcript
Welcome to the live discussion of the -- symposium, Abeta-targeting therapies in AD #1. So my name is Yona Levites. I'm from Center for Translational Research in Neurodegenerative Diseases in University of Florida. And my co-moderator is Dr. Luka Kulic, and he will introduce himself, and then all the members of our discussion will introduce themselves.
Thank you very much, Yona. Yes, I'm Luka Kulic. I'm a neurologist by training and am a medical director, working at Roche Pharma Research and Early Development in Basel, and leading several Alzheimer's disease programs approach. Then I'll hand over to Laura.
Thank you. My name is Laura Nisenbaum. It's a pleasure for me to be part of this session. I really appreciate the invitation. I lead the Diagnostic Pathway Group at Biogen and am also responsible for the biomarker strategy for aducanumab. Thanks.
Michelle? Sorry.
Okay. I'm Michelle Gee, and I'm
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
